We'll start our weekend-roundup jamboree with some news out of the American Society of Hematology meeting in Atlanta. So in a way this should be called, 'while you weren't' at ASH, but we're sticking with convention. Here are a few bits of late-stage clinical news out of the blood meeting:
- ASH: JNJ and Bayer said on Saturday that their Phase III Factor Xa inhibitor anticoagulant rivaroxaban was superior to enoxaparin (Lovenox) in preventing venous thromboembolism in patients following hip replacement surgery. Rivaroxaban is a once-daily oral, while Lovenox is injected. Boehringer Ingelheim's rival treatment dabigatran, a thrombin inhibitor, has begun a mid-stage trial in acute coronary syndrime says Reuters.
- ASH: Bayer, with Biogen Idec, also posted postive results in oncology, as the companies' Zevalin lymphoma therapy significantly increased progression-free survival in follicular lymphoma.
- ASH: Celgene's Revlimid added to dexamethasone in a Phase III study significantly boosted progression free survival in newly diagnosed multiple myeloma patients compared with dexamethasone alone.
- ASH: Adding Millennium's Velcade to standard of care in front-line multiple myeloma treatment "achieved a fourfold increase in complete remission rate," according to results of a Phase III study presented at ASH.
- MGI Pharma, the oncology and acute care specialist, was bought early today by Japanese pharmaco Eisai for $3.9 billion. You can read our first take here, and we'll no doubt have more to say on this later when we're, you know, awake.
No comments:
Post a Comment